AAS
RIGL icon

Avantax Advisory Services’s Rigel Pharmaceuticals RIGL Stock Holding History

Avantax Advisory Services’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-2,706
Closed -$42K – 887
2020
Q1 		$42K Sell
2,706
-805
-23% -$17.1K ﹤0.01% 780
2019
Q4 		$75K Buy
3,511
+1,295
+58% +$26.7K ﹤0.01% 808
2019
Q3 		$41K Buy
+2,216
New +$45.8K ﹤0.01% 562

Other funds holding RIGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TA
Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Avantax Advisory Services's RIGL Position: Q2 2020 in Review

Avantax Advisory Services sold out of Rigel Pharmaceuticals (RIGL) in Q2 2020, closing a stake of 2,706 shares — an estimated $42K sold.

Avantax Advisory Services first reported a position in RIGL in Q3 2019 and held it in 3 quarters. The position peaked at $75K in Q4 2019. 135 funds tracked by Wall St. Rank hold RIGL as of Q2 2020.

  • Avantax Advisory Services reported no remaining Rigel Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Avantax Advisory Services sold 2,706 Rigel Pharmaceuticals shares in Q2 2020, an estimated $42K.
  • Avantax Advisory Services first reported a position in Rigel Pharmaceuticals in Q3 2019 and held it in 3 quarters.
  • Avantax Advisory Services's Rigel Pharmaceuticals position peaked at $75K in Q4 2019.
  • 135 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2020.

Based on Avantax Advisory Services's 13F filing for Q2 2020, filed 6 Aug 2020.